TD Asset Management
KYTX icon

TD Asset Management’s Kyverna Therapeutics KYTX Stock Holding History

TD Asset Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Sell
145,682
-23,400
-14% -$208K ﹤0.01% 1049
2026
Q1 		$1.46M Sell
169,082
-53,714
-24% -$448K ﹤0.01% 1033
2025
Q4 		$2.09M Buy
222,796
+58,000
+35% +$431K ﹤0.01% 971
2025
Q3 		$989K Sell
164,796
-87,400
-35% -$349K ﹤0.01% 1094
2025
Q2 		$774K Buy
252,196
+161,954
+179% +$401K ﹤0.01% 1093
2025
Q1 		$174K Hold
90,242
– – ﹤0.01% 1199
2024
Q4 		$338K Hold
90,242
– – ﹤0.01% 1204
2024
Q3 		$472K Hold
90,242
– – ﹤0.01% 1304
2024
Q2 		$677K Buy
+90,242
New +$1.38M ﹤0.01% 1227

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

TD Asset Management's KYTX Position: Q2 2026 in Review

TD Asset Management reduced its Kyverna Therapeutics (KYTX) stake by 14% in Q2 2026, selling an estimated $208K and leaving 145,682 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1049.

TD Asset Management first reported a position in KYTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.09M in Q4 2025. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • TD Asset Management held 145,682 shares of Kyverna Therapeutics worth $1.3M as of Q2 2026.
  • TD Asset Management sold 23,400 Kyverna Therapeutics shares in Q2 2026, an estimated $208K.
  • Kyverna Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1049 holding.
  • TD Asset Management first reported a position in Kyverna Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • TD Asset Management's Kyverna Therapeutics position peaked at $2.09M in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.